Cargando…
Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway
LMB-100 (RG7787) is a recombinant immunotoxin, which kills mesothelin-expressing cancer cells and now being evaluated in phase 1 trials. To enhance the anti-tumor activity of LMB-100, we have searched for agents, already approved for cancer therapy, that can be combined with LMB-100 to increase its...
Autores principales: | Liu, Xiu-Fen, Zhou, Qi, Hassan, Raffit, Pastan, Ira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675634/ https://www.ncbi.nlm.nih.gov/pubmed/29152082 http://dx.doi.org/10.18632/oncotarget.20263 |
Ejemplares similares
-
Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
por: Pegna, Guillaume Joe, et al.
Publicado: (2022) -
cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition
por: Padmanabhan, Chandrasekhar, et al.
Publicado: (2017) -
Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors
por: El-Behaedi, Salma, et al.
Publicado: (2018) -
FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP
por: Tsuchiya, Yuichi, et al.
Publicado: (2015) -
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)